⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. (Q37990397)

26 August 2017

title

⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. (English)

1 reference

26 August 2017

0 references

1

1 reference

26 August 2017

Davide Campana

2

0 references

author name string

Paola Tomassetti

series ordinal

3

1 reference

26 August 2017

Stefano Fanti

series ordinal

4

1 reference

26 August 2017

publication date

1 February 2012

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

26 August 2017

published in

1 reference

26 August 2017

volume

39 Suppl 1

1 reference

26 August 2017

page(s)

S52-60

1 reference

Current status of gastrointestinal carcinoids

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Epidemiology of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Nuclear imaging of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1989-4

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging

21 January 2018

1 reference

12 December 2020

Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

1 reference

12 December 2020

Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.

1 reference

12 December 2020

Processing of generator-produced 68Ga for medical application.

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

10.1007/S00259-011-1989-4

Identifiers

DOI

1 reference

release_esubl5n6traexeemsrvrfmz47u

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/esubl5n6traexeemsrvrfmz47u

24 November 2022

mapped directly with Wikidata item

1 reference